AUB ScholarWorks

Browsing by Author "Fagon J.-Y."

Browsing by Author "Fagon J.-Y."

Sort by: Order: Results:

  • Rubinstein E.; Lalani T.; Corey G.R.; Kanafani Z.A.; Nannini E.C.; Rocha M.G.; Rahav G.; Niederman M.S.; Kollef M.H.; Shorr A.F.; Lee P.C.; Lentnek A.L.; Luna C.M.; Fagon J.-Y.; Torres A.; Kitt M.M.; Genter F.C.; Barriere S.L.; Friedland H.D.; Stryjewski (CARYJOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, 2011)
    Background: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods: Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired ...
  • Rubinstein E.; Lalani T.; Corey G.R.; Kanafani Z.A.; Nannini E.C.; Rocha M.G.; Rahav G.; Niederman M.S.; Kollef M.H.; Shorr A.F.; Lee P.C.; Lentnek A.L.; Luna C.M.; Fagon J.-Y.; Torres A.; Kitt M.M.; Genter F.C.; Barriere S.L.; Friedland H.D.; Stryjewski (CARYJOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, 2011)
    Background: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods: Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired ...
  • Rubinstein E.; Lalani T.; Corey G.R.; Kanafani Z.A.; Nannini E.C.; Rocha M.G.; Rahav G.; Niederman M.S.; Kollef M.H.; Shorr A.F.; Lee P.C.; Lentnek A.L.; Luna C.M.; Fagon J.-Y.; Torres A.; Kitt M.M.; Genter F.C.; Barriere S.L.; Friedland H.D.; Stryjewski (CARYJOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, 2011)
    Background: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods: Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired ...

Search AUB ScholarWorks

Browse

My Account